SAN FRANCISCO, Oct. 10 - Lexicon Genetics has licensed its gene-targeting isogenic DNA technology to US drug giant Pfizer, the companies announced on Wednesday.
Financial details of the agreement were not disclosed.
The non-exclusive internal research-use license is the second The Woodlands, Texas-based Lexicon has licensed to Pfizer, which also holds a non-exclusive license from Lexicon for internal research use of Lexicon's positive-negative selection technology.
"We are pleased that Pfizer has taken an additional license to our patented gene targeting technologies and believe the increased interest in our sublicense reflects the growing value that is associated with in vivo target validation," Arthur Sands, CEO of Lexicon, said in a statement.